<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; market</title>
	<atom:link href="http://www.tapanray.in/tag/market/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Revolutionizing Indian Pharma: The Rise of AI and Its Transformative Impact</title>
		<link>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact</link>
		<comments>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/#comments</comments>
		<pubDate>Thu, 13 Mar 2025 11:12:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game-changing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revolutionizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10883</guid>
		<description><![CDATA[I find it fascinating that some well-established consulting firms like E&#38;Y have recently published multiple reports on AI in the pharmaceutical industry. These reports, often released alongside industry events or as part of broader research initiatives, provide valuable insights rather than a &#8230; <a href="http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Expand Market Share Unleashing Digital Health Potential For All</title>
		<link>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=expand-market-share-unleashing-digital-health-potential-for-all</link>
		<comments>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/#comments</comments>
		<pubDate>Mon, 15 Nov 2021 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10609</guid>
		<description><![CDATA[“Advancement in digital health is currently restricted mainly to economically and socially privileged populations. Those having access, resources and basic digital skills, are reaping disproportionate benefits from the technology and other associated infrastructure available for this purpose. Unfortunately, underserved population, &#8230; <a href="http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Game-Changing Non-Covid Drug Approval In the Pandemic Milieu</title>
		<link>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu</link>
		<comments>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/#comments</comments>
		<pubDate>Mon, 11 Oct 2021 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[designation]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Glargine]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insuline]]></category>
		<category><![CDATA[interchangeable]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[milieu]]></category>
		<category><![CDATA[original]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Semglee]]></category>
		<category><![CDATA[superior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10595</guid>
		<description><![CDATA[Amid high decibel deliberations on Covid-19 pandemic, something similar to groundbreaking happened &#8211; involving Biosimilar drugs, in just a couple of months ago. On July 28, 2021, in the Eldorado of the pharma industry, the US-FDA approved  the first ‘interchangeable’ biosimilar drug, &#8230; <a href="http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-game-changing-non-covid-drug-approval-in-the-pandemic-milieu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unleashing Pharma’s New Potential In Changing Market Dynamics</title>
		<link>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleashing-pharmas-new-potential-in-changing-market-dynamics</link>
		<comments>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/#comments</comments>
		<pubDate>Mon, 07 Jun 2021 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote working]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TCS]]></category>
		<category><![CDATA[unleashing]]></category>
		<category><![CDATA[WFH]]></category>
		<category><![CDATA[work from home]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10525</guid>
		<description><![CDATA[Several pharma majors have started pondering in this space. This is evident from several recent developments, both in India, and also in other places of the world. One such articulation can be heard from the very top of the domestic &#8230; <a href="http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Changing Customer Behavior Pharma To Leverage AI For Better Engagement</title>
		<link>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement</link>
		<comments>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/#comments</comments>
		<pubDate>Mon, 05 Apr 2021 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[deep]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drops]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[feedback]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[machine]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[nasal]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10462</guid>
		<description><![CDATA[More than 55 million doses of Coronavirus vaccines were administered in India, reportedly, at the beginning of the last week of March 2021, in what is the world&#8217;s biggest inoculation drive. Notably, amid this mega initiative, the news media simultaneously reported that ‘India is facing a &#8230; <a href="http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-changing-customer-behavior-pharma-to-leverage-ai-for-better-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating A Unique Patient Experience By Listening To Patients Voice – An Imperative In The New Normal</title>
		<link>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal</link>
		<comments>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Mar 2021 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers. Covid-19]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[measuring]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[old normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10446</guid>
		<description><![CDATA[Acquiring deeper insight on the patient journey through a disease treatment process to create and enhance end-to-end patient experience, never assumed such critical importance, ever in the past. Without this realization, I reckon, even digitalization of any scale in the pharmaceutical &#8230; <a href="http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Greater Patient–Value To Excel With Repurposed Covid Brands</title>
		<link>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-greater-patient-value-to-excel-with-repurposed-covid-brands</link>
		<comments>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/#comments</comments>
		<pubDate>Mon, 23 Nov 2020 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antivirals]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[segments]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10335</guid>
		<description><![CDATA[Regular introduction of new molecules, line extensions or a Novel Drug delivery System (NDDS) has remained the life blood for pharma to rejuvenate a company’s product portfolio for driving organizational growth. But, Covid’s unprecedented and devastating assault on human lives &#8230; <a href="http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery</title>
		<link>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery</link>
		<comments>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/#comments</comments>
		<pubDate>Mon, 14 Sep 2020 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair drug pricing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[spending]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10259</guid>
		<description><![CDATA[Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health &#8230; <a href="http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Any Threat To Current Commercial Model Of ‘Gene Therapy’?</title>
		<link>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=any-threat-to-current-commercial-model-of-gene-therapy</link>
		<comments>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/#comments</comments>
		<pubDate>Mon, 30 Dec 2019 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CAR-T]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[current]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[disorders]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[genetic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9833</guid>
		<description><![CDATA[Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 &#160; One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers &#8230; <a href="http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/any-threat-to-current-commercial-model-of-gene-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
